Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.11 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
Recent Filing Shows That Rep. Scott Franklin Bought Over $16K Worth of Novo Nordisk Stock
 
Via Benzinga
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?
Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition. 
Via Benzinga
Is Novo Nordisk Gaining or Losing Market Support?
 
Via Benzinga
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.
From vaccines to fluoride and beef tallow, here's where Robert F. Kennedy Jr. is making changes to health care. 
Via Investor's Business Daily
Topics Government
Hims’ Weight Loss Expansion: Real Growth or Just Hype?
Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite? 
Via MarketBeat
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
5 Top Growth Stocks to Buy in the Stock Market Sell-Off
Via The Motley Fool
Topics Government
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Trump Administration Reverses Biden's Plan For Medicare Coverage Of Obesity Drugs Like Ozempic And Zepbound
CMS finalizes 2026 Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries. 
Via Benzinga
Topics Government
Retail Traders Prefer Novo Nordisk To Eli Lilly After Medicare Shuts Door On Obesity Drug Coverage — But There's More
However, Morgan Stanley sees limited impact on Lilly from the CMS decision as the proposed coverage appeared to apply only to a subset of the Medicare obesity population 
Via Stocktwits
Topics Government World Trade
Eli Lilly And Novo Nordisk Could Face Policy Shifts As FDA Oversight, Tariff Risks Mount
Needham hosted an expert to discuss potential impact of trade tariffs and personnel changes on healthcare equities. Generic drug market may be negatively affected. 
Via Benzinga
Topics World Trade
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): good value for what you're paying.
NOVO-NORDISK A/S-SPONS ADR may be an undervalued stock option. NYSE:NVO retains a strong financial foundation and an attractive price tag. 
Via Chartmill
Eli Lilly, Novo Stocks Dive After Medicare Excludes Weight-Loss Drugs
The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. 
Via Investor's Business Daily
Topics Government
Why Hims & Hers Health Stock Couldn't Beat the Market Today
Via The Motley Fool
Hims Dives After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch
It's true, the company can sell Lilly's tirzepatide. But that doesn't mean patients will buy it. 
Via Investor's Business Daily
Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Sales
Novo Nordisk saw its stock drop 21% year-to-date, pressured by weaker-than-expected obesity drug trial results. 
Via Benzinga
Novo Nordisk’s Controlling Shareholder Novo Holdings Reports Record Total Income, Investment Returns In 2024: Retail Stays Bullish
The company said that its earnings consist of income from dividends and the share repurchase programmes of Novo Group companies Novo Nordisk A/S and Novonesis A/S, as well as returns from its... 
Via Stocktwits
Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now?
Via The Motley Fool
Hims & Hers Health Stock Jumped Tuesday Afternoon: What Happened?
Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli Lilly And Co's (NYSE:LLY) Zepbound through its Telehealth platform. 
Via Benzinga
Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound
The deal allows Hims & Hers to sell Eli Lilly's Zepbound on its telehealth platform. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug
Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL trial finds Rybelsus lowers cardiovascular risk by 14%. 
Via Benzinga
Which Healthcare Stock Is the Best Buy Right Now?
Healthcare stocks provide a combination of upstarts with a high risk, high reward proposition to established firms that can be a defensive maneuver. 
Via MarketBeat
US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst
U.S. stock futures fell on Monday after three consecutive days of decline on Friday. Futures of benchmark indices were lower in premarket. 
Via Benzinga
While Wall Street Panicked, These 3 Hidden Small-Caps Exploded Last Week — One Surging A Jaw-Dropping 60%
As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks throughout the past week, a handful of small-caps defied the odds by posting... 
Via Benzinga
Topics Economy
Competitive Analysis In The ATTR-CM Field
Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the... 
Via Talk Markets
Topics Stocks / Equities
Is Hims & Hers Stock Too Cheap to Pass Up?
This high-growth stock may be cheaper than you think. 
Via The Motley Fool
Benzinga Bulls And Bears: Chevron, Microsoft, Nike — And Tariffs Have Automotive Sector Reeling
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Deal Dispatch: Bezos-Backed Crop Company Wilts, Tech Startup Nabs Napster For $207 Million
AT&T, Searchlight Capital Partners, Blackstone, I Squared Capital, and Morgan Stanley are all actively seeking to ink a deal. 
Via Benzinga
Novo Nordisk Stock Slips After BofA, Morgan Stanley Slash Price Targets – But Retail Goes Contrarian
Bank of America analysts said Novo Nordisk might miss first-quarter estimates. According to TheFly, they expect the company to lower its full-year sales guidance from 16%-24% at constant exchange rates... 
Via Stocktwits
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.